Premium
Oral and maxillofacial pathologies in young‐ and middle‐aged adults
Author(s) -
Almoznino G,
Zadik Y,
Vered M,
Becker T,
Yahalom R,
Derazne E,
Aframian DJ,
Czerninski R
Publication year - 2015
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1111/odi.12308
Subject(s) - medicine , malignancy , young adult , oral lichen planus , dermatology , middle age , pathology
Objective To evaluate the distribution of oral and maxillofacial pathologies ( OMFP s) and its association with patient age in young‐ and middle‐aged adults. Methods Distribution of histopathologically diagnosed OMFP s ( n = 385) treated during 2007–2010 was recorded and the association with patient age was retrospectively analyzed. Results The main diagnostic categories included benign exophytic lesions (45.3%), white benign lesions (13.5%), potentially malignant lesions/disorders (10.1%), intrabony lesions (9.8%), mucosal discoloration (7.8%), benign pigmented lesions (7.3%), chronic trauma/inflammation (3.9%), and oral malignancy (2.1%). Potentially malignant lesions/disorders as a diagnostic category were positively associated with age ( OR = 1.07 for 1 year; P < 0.001) and specifically the diagnoses of oral lichen planus ( OR = 1.04 for 1 year; P = 0.037) and dysplastic changes ( OR = 1.08 for 1 year; P = 0.013) that comprised this category. Pigmented melanocytic lesions were negatively associated with age ( OR = 0.94 for 1 year; P = 0.039) as well as benign/reactive exophytic lesions ( OR = 0.98 for 1 year; P = 0.038), the latter included the histopathological diagnosis of benign salivary gland pathologies ( OR = 0.90 for 1 year; P < 0.001). Conclusion This study provided baseline information regarding the distribution OMFP s among young‐ and middle‐aged adults. It is important to highlight the high frequency of potentially malignant lesions/disorders and oral malignancy in young‐ and middle‐aged adults, as these lesions require lifelong follow‐up.